Table 2 Primary and secondary outcomes for each group
Group RR (N = 102) | Group RA (n = 102) | p value | |
|---|---|---|---|
Primary outcome | |||
PONV n(%) | 2 (2.0%) | 12 (11.7%) | 0.006* |
Secondary outcomes | |||
Time to awakening, mean ± SD, s | 200.6 ± 94.6 | 283.5 ± 183.1 | < 0.001* |
PACU length of stay, mean ± SD, s | 354.1 ± 66.8 | 371.8 ± 67.0 | 0.639 |
Total remimazolam, mean ± SD, mg | 22.3 ± 4.7 | 21.7 ± 4.5 | 0.722 |
Adverse events, n(%) | |||
Low SpO2 | 15 (14.7%) | 22 (21.6%) | 0.203 |
Bradycardia | 3 (2.9%) | 3 (2.9%) | 1.000 |
Hypotension | 8 (7.8%) | 10 (9.8%) | 0.622 |
Body movement | 30 (29.4%) | 27 (26.5%) | 0.640 |
Total remifentanil, mean ± SD, µg | 69.1 ± 21.6 | --- |